vs
Side-by-side financial comparison of Chatham Lodging Trust (CLDT) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
Chatham Lodging Trust is the larger business by last-quarter revenue ($67.7M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). Chatham Lodging Trust runs the higher net margin — 6.8% vs -83.0%, a 89.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs -9.8%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs -0.5%).
Chatham Lodging Trust is a publicly traded real estate investment trust that invests in, owns, and operates upscale extended-stay and select-service premium hotel properties primarily across high-demand urban and suburban markets in the United States. Its portfolio targets assets with strong occupancy rates and steady cash flow from business and leisure traveler segments.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
CLDT vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $67.7M | $57.3M |
| Net Profit | $4.6M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | 15.9% | -82.2% |
| Net Margin | 6.8% | -83.0% |
| Revenue YoY | -9.8% | 36.9% |
| Net Profit YoY | 369.9% | -9.6% |
| EPS (diluted) | $0.05 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $67.7M | $57.3M | ||
| Q3 25 | $78.4M | $51.3M | ||
| Q2 25 | $80.3M | $48.5M | ||
| Q1 25 | $68.6M | $32.7M | ||
| Q4 24 | $75.1M | $41.8M | ||
| Q3 24 | $87.2M | $33.3M | ||
| Q2 24 | $86.5M | $29.1M | ||
| Q1 24 | $68.4M | $26.0M |
| Q4 25 | $4.6M | $-47.5M | ||
| Q3 25 | $3.5M | $-52.9M | ||
| Q2 25 | $5.4M | $-46.6M | ||
| Q1 25 | $1.5M | $-49.5M | ||
| Q4 24 | $-1.7M | $-43.3M | ||
| Q3 24 | $4.3M | $-43.6M | ||
| Q2 24 | $6.8M | $-32.3M | ||
| Q1 24 | $-5.2M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | 40.7% | 90.9% | ||
| Q3 24 | 44.7% | 88.5% | ||
| Q2 24 | 46.1% | 89.9% | ||
| Q1 24 | 38.9% | 89.2% |
| Q4 25 | 15.9% | -82.2% | ||
| Q3 25 | 12.7% | -102.6% | ||
| Q2 25 | 14.8% | -93.4% | ||
| Q1 25 | 12.1% | -143.7% | ||
| Q4 24 | 7.5% | -98.6% | ||
| Q3 24 | 14.3% | -132.0% | ||
| Q2 24 | 16.3% | -139.2% | ||
| Q1 24 | 1.4% | -538.7% |
| Q4 25 | 6.8% | -83.0% | ||
| Q3 25 | 4.5% | -103.1% | ||
| Q2 25 | 6.7% | -96.1% | ||
| Q1 25 | 2.2% | -151.4% | ||
| Q4 24 | -2.3% | -103.6% | ||
| Q3 24 | 4.9% | -131.2% | ||
| Q2 24 | 7.9% | -110.9% | ||
| Q1 24 | -7.6% | -544.4% |
| Q4 25 | $0.05 | $-0.73 | ||
| Q3 25 | $0.03 | $-0.82 | ||
| Q2 25 | $0.07 | $-0.75 | ||
| Q1 25 | $-0.01 | $-0.81 | ||
| Q4 24 | $-0.08 | $-0.71 | ||
| Q3 24 | $0.05 | $-0.73 | ||
| Q2 24 | $0.10 | $-0.55 | ||
| Q1 24 | $-0.15 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.4M | $388.9M |
| Total DebtLower is stronger | $338.9M | — |
| Stockholders' EquityBook value | $740.8M | $139.1M |
| Total Assets | $1.2B | $480.2M |
| Debt / EquityLower = less leverage | 0.46× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.4M | $388.9M | ||
| Q3 25 | $13.2M | $416.1M | ||
| Q2 25 | $17.2M | $291.0M | ||
| Q1 25 | $18.6M | $314.5M | ||
| Q4 24 | $20.2M | $320.6M | ||
| Q3 24 | $19.3M | $298.4M | ||
| Q2 24 | $10.6M | $319.1M | ||
| Q1 24 | $72.3M | $201.2M |
| Q4 25 | $338.9M | — | ||
| Q3 25 | $338.8M | — | ||
| Q2 25 | $351.2M | — | ||
| Q1 25 | $381.1M | — | ||
| Q4 24 | $406.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $740.8M | $139.1M | ||
| Q3 25 | $749.4M | $148.8M | ||
| Q2 25 | $754.1M | $-11.9M | ||
| Q1 25 | $754.7M | $18.9M | ||
| Q4 24 | $758.2M | $21.7M | ||
| Q3 24 | $765.3M | $11.2M | ||
| Q2 24 | $766.5M | $39.3M | ||
| Q1 24 | $765.0M | $61.6M |
| Q4 25 | $1.2B | $480.2M | ||
| Q3 25 | $1.2B | $506.9M | ||
| Q2 25 | $1.2B | $372.7M | ||
| Q1 25 | $1.2B | $386.7M | ||
| Q4 24 | $1.3B | $392.3M | ||
| Q3 24 | $1.3B | $363.6M | ||
| Q2 24 | $1.3B | $381.8M | ||
| Q1 24 | $1.3B | $258.7M |
| Q4 25 | 0.46× | — | ||
| Q3 25 | 0.45× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.50× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $64.1M | $-25.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 13.90× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.1M | $-25.4M | ||
| Q3 25 | $25.6M | $-26.6M | ||
| Q2 25 | $22.1M | $-23.3M | ||
| Q1 25 | $4.2M | $-40.4M | ||
| Q4 24 | $73.8M | $-18.8M | ||
| Q3 24 | $28.8M | $-25.2M | ||
| Q2 24 | $25.2M | $-29.1M | ||
| Q1 24 | $6.9M | $-40.7M |
| Q4 25 | 13.90× | — | ||
| Q3 25 | 7.24× | — | ||
| Q2 25 | 4.10× | — | ||
| Q1 25 | 2.73× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 6.78× | — | ||
| Q2 24 | 3.68× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLDT
| Occupancy | $61.5M | 91% |
| Hotel Other | $4.2M | 6% |
| Food And Beverage | $1.8M | 3% |
| Hotel | $1.1M | 2% |
RYTM
Segment breakdown not available.
